ClinicalTrials.gg
Not yet recruitingNCT07546617Updated Nov 13, 2026

In Vivo Imaging of the Olfactory Epithelium Using Confocal Laser Endomicroscopy

An Early Phase 1 interventional study of CONVIVO system and Fluorescein injection, USP 10% in Endonasal Surgery, Endoscopic Sinus Surgery and Olfactory Dysfunction, sponsored by Dartmouth-Hitchcock Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Dartmouth-Hitchcock Medical Center · Early Phase 1, Interventional, and Diagnostic

How we know

Updated Nov 13, 2026Now Not yet recruitingStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Anosmia with a site in United States — 17 open to participants now, 20 under way, 1 of them phase 3. Anosmia · United States.

Planned enrollment
28th of 43
36 · median 51
Started
2026
with 5 others
Phase 1
4 of 59
1 open now
Primary completion
2027-04
later than 8 of 19 live
Registered
52nd of 59
by date

Among the 59 studies in Anosmia with a site in United States, this one is the 28th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2026, is one of 4 in phase 1, reaches primary completion later than 8 of the 19 other live ones, and was the 52nd registered.

Anosmia

180 studies on the registry are indexed under Anosmia; 45 are open to participants now.

Browse Anosmia studies →

Open to participants now

17 of the 59 studies in Anosmia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Anosmia studies recruiting now, 14 (45%) set no upper age limit and 9 (29%) stop at 75 or younger; 3 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Anosmia with a site in United States, or all of them as a file.
02

Study summary

This research is being done to better characterize the part of the nose that helps people smell. Currently, the only ways to study smell loss mostly rely on how people report it, rather than being able to see the underlying structures directly. In this study, the team will use a special microscope (Confocal Laser Endomicroscopy (CLE)), originally developed for brain tissue, to look at the part of the nose that helps to detects smell. The study team hopes to identify the tiny structures in that area and see how they might be different in people who have smell loss compared to those who do not. Participation in the study includes completing a smell test (Sniffin' Sticks Extended test), a cognitive screening test, and two questionnaires.

Read the detailed description

Aim 1: Evaluate the feasibility of in vivo CLE imaging of the olfactory cleft and nasal turbinate and determine whether CLE features correlate with validated psychophysical olfactory testing and patient-reported quality-of-life measures.

The study team will obtain preoperative Sniffin' Sticks threshold-discrimination-identification (TDI) scores and questionnaires in 36 surgical patients recruited from NH and VT, followed by intraoperative CLE imaging after intravenous fluorescein. CLE images will be assessed for epithelial features such as neuronal loss, epithelial thinning, basement membrane irregularity, and inflammatory changes.

Aim 2: Compare in vivo CLE imaging features with histopathologic findings from superior turbinate tissue, when available, to identify candidate in vivo imaging biomarkers. When routine surgery includes removal of superior turbinate tissue, CLE images will be paired with histopathology to assess concordance in features such as neuronal density, sustentacular cell integrity, and inflammation.

03

Conditions studied

  • Endonasal Surgery
  • Endoscopic Sinus Surgery
  • Olfactory Dysfunction

Browse trials for

Keywords

  • Confocal Laser Endomicroscopy
  • Endoscopic Sinus Surgery
  • Smell Loss
  • Endonasal Skull Base Surgery
  • Olfactory Dysfunction
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years
  • Undergoing endoscopic sinus or endonasal skull base surgery while under - general anesthesia where the nasal turbinate is accessible
  • Able to complete study questionnaires and psychophysical smell testing
  • Able to provide .

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to fluorescein
  • Pregnancy
  • Medical instability precluding participation
  • Severe anatomic obstruction preventing safe access to the olfactory cleft and nasal turbinate
  • Any other safety concern identified by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Other
    Target Group (Patients with Olfactory Complaints)

    Patients who have olfactory complaints and are undergoing endoscopic sinus or endonasal skull base surgery while under general anesthesia where the nasal turbinate is accessible, per their standard of care.

    Device: CONVIVO system · Drug: Fluorescein injection, USP 10%

  • Other
    Control Group

    Controls will consist of surgical patients without subjective olfactory complaints and with expected normal psychophysical testing. Patients who are already undergoing endoscopic sinus or endonasal skull base surgery while under general anesthesia where the nasal turbinate is accessible, per their standard of care.

    Device: CONVIVO system · Drug: Fluorescein injection, USP 10%

Interventions

  • DeviceCONVIVO system

    Approximately 2-5 minutes following administration of FNa in situ imaging will be performed by the participating surgeon ensuring proper technique. Prior to entering the surgical field, the probe will be covered in a disposable sterile sheath that is manufactured with quality assurance for this purpose. The probe will gently be held against the tissue interface while imaging occurs. Following image acquisition, a pathologist present in the operating room, will review and capture each image.

  • DrugFluorescein injection, USP 10%

    Sodium fluorescein will be administered intravenously or topically (applied directly to nasal mucosa) at doses of 5-10 mg/kg (not exceeding 20 mg/kg cumulative). Administration will be performed by the anesthesia team in the operating room.

    Also known as: AK-FLUOR, FNa

06

What researchers measure

Primary outcomes

  1. Evaluate the feasibility of in vivo CLE imaging of the olfactory cleft and nasal turbinate and determine whether CLE features correlate with validated psychophysical olfactory testing and patient-reported quality-of-life measures.

    (1) High feasibility (≥85% interpretable images); (2) identifiable CLE signatures associated with OD severity; (3) significant correlations between CLE features, TDI scores, and symptom burden.

    Time frame: On day of Surgery, Day 0

Secondary outcomes

  1. Compare in vivo CLE imaging features with histopathologic findings from superior turbinate tissue, when available, to identify candidate in vivo imaging biomarkers.

    When routine surgery includes removal of superior turbinate tissue, CLE images will be paired with histopathology to assess concordance in features such as neuronal density, sustentacular cell integrity, and inflammation. Expected Outcomes: Identification of CLE features corresponding to gold-standard histopathology, generating preliminary in vivo imaging biomarkers.

    Time frame: On day of Surgery, Day 0

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Apr 2027, 5 months later.

Start moved twice since we started tracking on Sep 25, 2026: Apr 2026 → Nov 2026, last on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2026
First posted
Apr 23, 2026
StartEst.
Nov 30, 2026was Apr 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Not yet recruiting
changed Oct 20, 2026
Start date
Apr 28, 2026→Nov 30, 2026
moved 2 times, Oct 20, 2026 – Nov 13, 2026
Contact
Study contact now listed: added M•••@hitchcock.org · •••2054; added R•••@hitchcock.org · •••8123. See the current contact
Oct 20, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Dartmouth-Hitchcock Medical Center · Lebanon, United StatesContact added R•••@hitchcock.org · •••8123Contact added (no phone or email listed)
Oct 20, 2026
Show all 3 updates
  1. Nov 13, 2026
    Start date Nov 3, 2026→Nov 30, 2026
    + 1 other change: verification date
  2. Oct 20, 2026
    Active, not recruiting→Not yet recruiting
    Start date Apr 28, 2026→Nov 3, 2026
    Contact Study contact now listed: added M•••@hitchcock.org · •••2054; added R•••@hitchcock.org · •••8123. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Dartmouth-Hitchcock Medical Center · Lebanon, United StatesContact added R•••@hitchcock.org · •••8123Contact added (no phone or email listed)
  3. Oct 15, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07546617
Responsible party
Ryan.E.Little (Director of the Sinus Research Center Assistant Professor of Surgery, Geisel School of Medicine, Dartmouth, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Apr 23, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Michaela M Geffert, MS
Contact
Michaela.M.Geffert@Hitchcock.org
603-650-2054
Ryan E Little, MD
Contact
Ryan.E.Little@Hitchcock.org
603-650-8123

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion